Madopar

Valsts: Austrālija

Valoda: angļu

Klimata pārmaiņas: Department of Health (Therapeutic Goods Administration)

Aktīvā sastāvdaļa:

Levodopa; Benserazide hydrochloride; Benserazide

Pieejams no:

Roche Products Pty Ltd

Klase:

Medicine Registered

Lietošanas instrukcija

MADOPAR
®

_(levodopa and benserazide)_
CONSUMER MEDICINE INFORMATION

WHAT IS IN THIS LEAFLET
This leaflet answers some common
questions about MADOPAR tablets
and capsules.
It does not contain all the available
information.
It does not take the place of talking to
your doctor or pharmacist.
All medicines have risks and
benefits. Your doctor has weighed
the risks of you taking MADOPAR
against the benefits they expect it
will have for you.
If you have any concerns about
taking this medicine, ask your doctor
or pharmacist.
KEEP THIS LEAFLET WITH THE MEDICINE.
You may need to read it again.
WHAT MADOPAR IS
USED FOR
The name of your medicine is
MADOPAR. It contains two active
ingredients called levodopa and
benserazide.
MADOPAR belongs to a group of
medicines called antiparkinsonian
agents and is used for the treatment
of Parkinson's disease.
Antiparkinsonian agents are used to
treat Parkinson's disease and work on
the central nervous system. The
symptoms of Parkinson's disease are
caused by a deficiency of a natural
substance in the brain called
Dopamine. MADOPAR helps to
replace this substance. By improving
muscle control, MADOPAR allows
more normal movements of the body.
The symptoms of patients suffering
from Parkinson's disease can be
reduced by taking this medicine.
MADOPAR does not, however, cure
the disease, since the cause of the
dopamine deficiency within the brain
is not removed.
Your doctor, however, may have
prescribed MADOPAR for another
purpose.
ASK YOUR DOCTOR IF YOU HAVE ANY
QUESTIONS WHY MADOPAR HAS
BEEN PRESCRIBED FOR YOU.
This medicine is available only with
a doctor's prescription.
BEFORE YOU TAKE
MADOPAR
_DO NOT TAKE MADOPAR IF:_
•
you have had an allergic reaction
to any of the ingredients listed in
the Ingredients section of this
leaflet
•
you have taken a non-selective
monoamine oxidase inhibitor
(MAOI) medicine such as
tranylcypromine or phenelzine
within the last 2 weeks
•
you have taken a combination of
a selective MAO-A inhibitor such
as moclobemide with a selective
M

Produkta apraksts

r 

Madopar
®
 PI 100525
_ _
_ _
_ _
1 of 12 
CDS 5.0 
NAME OF THE MEDICINE 

MADOPAR 
(levodopa + benserazide) 

For the treatment of Parkinson's disease. 

MADOPAR is a combination of levodopa and the dopa decarboxylase
inhibitor, benserazide 
(DL-2'-(2,3,4-trihydroxybenzyl) serine hydrazide), present as the
hydrochloride, in the ratio of 4:1. 

Structural formula: 

CAS: benserazide:  322 35 0   

CAS: levodopa:  59 92 7 

DESCRIPTION 

The various MADOPAR preparations contain the following excipients: 
_ _
_MADOPAR Tablets:_ 
Both MADOPAR and MADOPAR 125 tablets contain mannitol,
microcrystalline cellulose, 
crospovidone, magnesium stearate, pregelatinised maize starch,
ethylcellulose, anhydrous calcium 
hydrogen phosphate, colloidal anhydrous silica, docusate sodium, iron
oxide red. 
_ _
_MADOPAR Rapid 62.5 and MADOPAR Rapid 125 Tablets: _
MADOPAR Rapid tablets contain citric acid, starch- maize,
microcrystalline cellulose, magnesium 
stearate. 

_MADOPAR Capsules: _
MADOPAR, MADOPAR 62.5 and MADOPAR 125 capsules all contain
microcrystalline cellulose, 
talc, povidone, magnesium stearate, indigo carmine,
titanium dioxide, iron oxide (red, yellow or 
black), gelatin.  MADOPAR 62.5 also contains mannitol. 

_MADOPAR HBS_ capsules contain mannitol
, 
talc, povidone, magnesium stearate, calcium hydrogen 
phosphate, hypromellose, hydrogenated vegetable oil, indigo carmine,
iron oxide yellow, titanium 
dioxide, gelatin and TEKPRINT SW-1102 Red Ink used as a printing ink.

PHARMACOLOGY 

Levodopa is the metabolic precursor of dopamine.  The latter is
severely depleted in the striatum 
pallidum and substantia nigra of Parkinsonian patients and it is
considered that the administration of 
levodopa raises the level of available dopamine in these centres.
 The major portion of a levodopa 
r 

Madopar
®
 PI 100525
_ _
_ _
_ _
2 of 12 
CDS 5.0 
dose, however, is decarboxylated in tissues outside the bra